MetaCap

AbbVie (ABBV) vs Novartis (NVS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AbbVie (ABBV) has outperformed Novartis (NVS) over the past year, gaining 21.1% versus a gain of 18.2%. Over five years, ABBV leads with a +145.6% price change compared with +86.5% for NVS. AbbVie is the larger company by market cap ($505.89 billion vs $284.18 billion), about 1.8 times the size.

On valuation, Novartis trades at a lower forward P/E (15.1x vs 17.6x for AbbVie). Novartis offers the higher dividend yield (3.10% vs 2.42%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABBV+21.13%NVS+18.19%
+35%+8%-19%
Nov 21, 20251 yearNov 20, 2026
ABBV+146.21%NVS+84.26%
+162%+73%-16%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABBV versus NVS key metrics
MetricABBVNVS
Share price$286.20$150.47
Market cap$505.89B$284.18B
1-day change+0.94%-0.50%
YTD return+25.26%+9.14%
1-year return+21.13%+18.19%
5-year return+145.64%+86.46%
P/E ratio (TTM)49.1828.72
Forward P/E17.6515.15
EPS (TTM)$5.82$5.24
Dividend yield2.42%3.10%
Annual dividend$6.92$4.67
Revenue (latest FY)$61.16B—
Revenue growth (YoY)+8.57%—
Net income (latest FY)$4.23B$13.98B
Gross margin70.24%—
Operating margin24.65%—
Net margin6.91%—
52-week high$302.93$170.46
52-week low$190.75$126.50
Distance from 52-week high-5.52%-11.73%
Analyst consensusbuyhold
Avg. price target upside+9.76%+4.41%
Average volume4.84M2.18M
Shares outstanding1.77B1.89B
Employees57,00075,267
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AbbVie trades at a higher earnings multiple (49.2x vs 28.7x trailing P/E).

About AbbVie

ABBV stock →

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 57,000 employees

About Novartis

NVS stock →

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 75,267 employees

ABBV vs NVS FAQ

Which is bigger, AbbVie or Novartis?

AbbVie (ABBV) is larger, with a market capitalization of $505.89B compared with $284.18B for Novartis (NVS).

Which stock has performed better over the past year, ABBV or NVS?

ABBV returned +21.13% over the past 12 months, compared with +18.19% for NVS (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, ABBV or NVS?

NVS has the lower trailing P/E at 28.7, versus 49.2 for ABBV. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, AbbVie or Novartis?

Novartis has the higher yield at 3.10%, compared with 2.42% for AbbVie.

Are AbbVie and Novartis in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons